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Abstract
Background: Sexual dimorphism in DNA methylation levels is a recurrent epigenetic feature in different human cell
types and has been implicated in predisposition to disease, such as psychiatric and autoimmune disorders. To
elucidate the genetic origins of sex-specific DNA methylation, we examined DNA methylation levels in fibroblast
cell lines and blood cells from individuals with different combinations of sex chromosome complements and sex
phenotypes focusing on a single autosomal region––the differentially methylated region (DMR) in the promoter of
the zona pellucida binding protein 2 (ZPBP2) as a reporter.
Results: Our data show that the presence of the sex determining region Y (SRY) was associated with lower
methylation levels, whereas higher X chromosome dosage in the absence of SRY led to an increase in DNA
methylation levels at the ZPBP2 DMR. We mapped the X-linked modifier of DNA methylation to the long arm of
chromosome X (Xq13-q21) and tested the impact of mutations in the ATRX and RLIM genes, located in this region,
on methylation levels. Neither ATRX nor RLIM mutations influenced ZPBP2 methylation in female carriers.
Conclusions: We conclude that sex-specific methylation differences at the autosomal locus result from interaction
between a Y-linked factor SRY and at least one X-linked factor that acts in a dose-dependent manner.
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Background
Recent genome-wide studies of DNA methylation in hu-
man cells have detected hundreds to thousands of auto-
somal loci where methylation levels differ between the
sexes [1–5]. It has been proposed that sex-specific differ-
ences in methylation levels contribute to sexual di-
morphism in complex phenotypes such as early
cognitive processes [4], pancreatic islet function [1],
predisposition to asthma [6], and psychiatric disorders
[5]. While differences in methylation of X-linked genes
are explained by X-chromosome inactivation, the cause
of sex-specific methylation of autosomal loci remains
elusive with the two main suspects: the sex chromosome
complement and gonadal hormones. The goal of this
study was to determine if the sex chromosomes contrib-
ute to sexual dimorphism in autosomal DNA methyla-
tion in human cells.
Mammalian males and females have different sex
chromosome complements (XX in females and XY in
males). The sex chromosome complement determines
gonadal sex, which in turn defines production of gonadal
hormones. The ensemble of current evidence suggests
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that both major factors, the sex chromosome comple-
ment and gonadal hormones either acting separately or
in concert lead to sexual dimorphism in a wide array of
phenotypes (reviewed in [7, 8]).
Sex-specific differences in phenotypes and gene ex-
pression patterns have been documented in different
species from Drosophila to humans ([9–12]. Sexually di-
morphic expression is seen in genes residing on the sex
chromosomes, as well as autosomal genes. Expression of
certain autosomal genes depends on the sex chromo-
some dosage, whereas other autosomal genes are con-
trolled by sex hormones, as demonstrated in mice and
humans [13–16]. In mice, about 10% of autosomal genes
have different expression levels between males and
females in somatic cells [17]. Most of these differences
depend on the sex of the mouse; however, expression
levels of hundreds of genes depend on the sex chromo-
some complement [13]. Sexual dimorphism in auto-
somal gene expression may result from different doses
of transcription factors that are encoded by the sex
chromosome-linked genes, especially those X-linked
genes that escape X-inactivation. It may also arise as a
consequence of sex-specific differences in methylation
levels of regulatory elements. In humans, most sexually
dimorphic autosomal differentially methylated regions
have higher methylation levels in females [1, 2, 18],
whereas repetitive elements have higher methylation in
males [2, 19–23]. In females with Turner syndrome and
monosomy X, global DNA methylation levels are lower
than in 46,XX females, but higher than in 46,XY males
[24, 25]. This suggests that both sex chromosomes as
well as gonadal hormones contribute to the
establishment or maintenance of global DNA methyla-
tion patterns.
Variation in DNA methylation often correlates with
variation in chromatin modifications. Enhancer-specific
active chromatin marks, H3K27ac and H3K4me1, co-
localize with loci that show sex-specific differences in
methylation in the mouse liver [26]. Moreover, the ana-
lysis of combined data from the ENCODE and Roadmap
Epigenomics projects suggests that sex-specific differ-
ences in epigenetic marks are more likely to occur at
enhancer regions and “bivalent” regions that carry both
active and repressive chromatin marks [27].
To elucidate the genetic mechanisms contributing to
sexual dimorphism in DNA methylation, we asked
whether the sex chromosome complement influenced
DNA methylation levels in human cells (Additional file 1:
Figure S1). To address this question, we focused on a
single autosomal differentially methylated region (DMR)
located within the promoter/enhancer region of the
human zona pellucida binding protein 2 gene (ZPBP2)
and used it as a marker DMR. DNA methylation of the
ZPBP2 DMR shows robust differences between males
and females in different tissues/cell types [2, 4, 6, 28].
Here, we show that both the Y and X chromosomes con-
trol ZPBP2 methylation levels.
Methods
Subjects
DNA samples from the peripheral blood of five carriers
of Xq13-q21 duplications with known boundaries of
duplicated regions [29, 30] were used for methylation
analysis. Three carriers of ATRX, chromatin remodeler
(ATRX) mutations c.7366_7367insA [31], eight heterozy-
gous carriers of ring finger protein, LIM domain inter-
acting (RLIM) gene mutations p.Arg387Cys, and six
non-carrier family members were also included in the
study [32].
The DNA samples from males and females from the
Saguenay-Lac-Saint-Jean (SLSJ) asthma familial collec-
tion were used as additional controls to compare methy-
lation levels between males, females, and female carriers
of X chromosomal duplications and mutations in X-
linked genes [6, 28]. We therefore used ZPBP2 methyla-
tion data from previously published works as a reference
for methylation levels in peripheral blood cells (PBC).
All experiments were conducted in accordance with
the Canadian Tri-Council Policy Statement of Ethical
Conduct for Research Involving Humans and approved
by the REB of the MUHC.
DNA samples from fibroblast cell lines
The DNA samples extracted from untransformed
human fibroblast cell lines were purchased from the
Coriell Cell Repository (Camden, New Jersey, USA).
Information on karyotype, genomic positions of trans-
location/deletion breakpoints, sex, age, number of pas-
sages, and the presence or absence of sex-determining
region Y (SRY) were obtained from the Coriell Institute
for Medical Research website [33]. If no SRY information
was available, the samples were genotyped for SRY by
PCR (primers are listed in Additional file 2: Table S1).
Cell lines and their characteristics are listed in
Additional files 3 and 4: Tables S2 and S3.
DNA methylation assays
The DNA samples were treated with sodium bisulfite
using the EpiTect Bisulfite Kit (Qiagen) per manufac-
turer’s protocol with modifications. The incubation step
was extended by one cycle of 5 min at 95 °C and 2 h at
60 °C before holding at room temperature overnight
until purification. The samples were purified according
to the manufacturer’s protocol, dried at 56 °C for 5 min,
and eluted in 40 μl (2 × 20 μl) of the elution buffer sup-
plied with the kit.
Pyrosequencing methylation assays for the ZPBP2
promoter/enhancer region were carried as previously
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described [6, 28]. The assay interrogates 11 CGs located
near the transcriptional start site of ZPBP2
(Additional file 5: Figure S2). This region is referred to as
ZPBP2 DMR from this point on. Methylation was assayed
using the PyroMark Q24 Advanced platform (Qiagen) and
PyroMark Q24 Advanced CpG Reagents. The assay was
conducted using separate sequencing primers
(Additional file 2: Table S1). The results were analyzed by
the PyroMark Q24 Advanced 3.0.0 software (Qiagen).
Sodium bisulfite sequencing assays to interrogate methyla-
tion of 51 CGs of the ZPBP2 promoter region were con-
ducted as previously described [34] (Additional file 5:
Figure S2). The ZPBP2 DMR targeted by pyrosequencing
overlaps with CGs 26–35 of the sodium bisulfite sequen-
cing ZPBP2 methylation assay. Sanger sequencing of
clones was performed by the McGill University and
Genome Quebec sequencing platform.
Statistical analysis
To study the influences of phenotypic sex and sex
chromosome complement on the methylation patterns in
these cell lines, ZPBP2 DMR methylation was analyzed in
36 fibroblast cell lines: 13 cell lines from 46,XX females, 7
from 46,XY males, 3 from 46,XX males, 4 from 46,XY
females, 7 from 45, X females, one from a 49,XYYYY
male, and one from a 48/49,XXXY/XXXXY male
(Additional file 3: Table S2). The ZPBP2 pyrosequencing
methylation assay interrogates 11 CGs [6]. Inconsistent
quality measures were found at CG1, and therefore, 10
CGs were used for further analyses. The data were missing
for at least one of the 10 CGs in seven of the 36 assayed
cell lines. Therefore, only 29 fibroblast cell lines were
included in the principal component (PC) analysis
(Additional file 3: Table S2 and Additional file 6: Table S4).
To improve the signal to noise ratio, the first PC of
the 10 CGs was calculated to summarize the methylation
data. This PC was plotted against methylation data and
multiplied by −1 to ensure that the PC was positively
correlated with general methylation trends; the resulting
oriented first PC was used as the dependent variable in
subsequent linear models. Since the methylation levels
at the 10 CGs are correlated, to perform separate ana-
lyses would lead to unnecessary multiple tests whereas
the principal component captures the primary trend
across the region.
Considering the available distribution of X and Y
chromosome numbers, observations were grouped to
compare samples from cell lines with one X chromo-
some (coded as “0”) to samples with two or more X
chromosomes (coded as “1”). The presence of the SRY
locus was coded as “1,” and absence as “0” (see Table 1).
Relationships between the first PC of methylation and
sex phenotype, presence of the Y chromosome, presence
of the SRY region, number of X chromosomes, donor’s
age, and number of passages were first explored descrip-
tively by fitting separate linear regressions. Then, step-
wise regression was used to obtain our final model, with
model selection criterion based on likelihood ratio tests,
with p = 0.10 for variable removal and p = 0.05 for vari-
able inclusion. Likelihood ratio tests were used instead
of Wald tests or score tests since the asymptotic conver-
gence is often better in small sample sizes [35]. The
starting model used for stepwise regression included
covariates: sex, age, passage number, number of Y chro-
mosomes, as well as main effects, and the interaction for
the presence of SRY and number of X chromosomes.
Results
The presence of the SRY region and the number of X
chromosomes influence ZPBP2 methylation levels.
To test the impact of the sex-chromosome comple-
ment on autosomal DNA methylation levels in human
cells, as a first step, we used human non-transformed
fibroblast cell lines derived from donors with different
combinations of sex-chromosome complement and sex
that would permit separating the effects of sex chromo-
somes from those of sex phenotype (Additional file 3:
Table S2 and Additional file 1: Figure S1). We selected
the ZPBP2 DMR located within the ZPBP2 promoter as
a marker of sex-specific differences in methylation levels.
Previous studies showed robust sex-specific differences
in DNA methylation in PBC, higher methylation levels
in females, and differences in methylation greater than
5% in this region [2, 4, 6, 28]. We analyzed ZPBP2 DMR
methylation levels in 36 fibroblast cell lines with differ-
ent combinations of sex chromosome complement and
sex phenotype (Fig. 1a). Of these, 29 cell lines had
complete data for the 10 CGs of the ZPBP2 DMR and
were used for PCA: these included 11 cell lines from
46,XX females; 4––from 46,XY males; 3––from 46,XX
males; 3––from 46,XY females, 6––from 45,X individ-
uals; one from a 49,XYYYY male, and one from a 48/
49,XXXY/XXXXY male (Additional file 7: Figure S3 and
Additional file 6: Table S4).
Methylation levels of the ZPBP2 DMR in fibroblast
cell lines, summarized by their first PC, were analyzed to
examine different combinations of sex phenotype and
sex chromosome complement (Fig. 1b). The first PC
captures 59.2% of the total variation (Additional file 7:
Figure S3). After grouping the independent variables of
interest, there were 14 samples with one X chromosome
Table 1 Counts of samples by SRY and number of X
chromosomes in fibroblast cell lines
Number of X chromosomes One Two or more
SRY absent 3 12
SRY present 11 3
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and 15 with two or more X chromosomes, and there
were 15 samples with SRY and 14 samples without SRY.
A number of initial linear models were fit to provide a
general description of the effects of potential covariates on
methylation. When sex phenotype, passage number, num-
ber of Y chromosomes, and age were, one at a time,
regressed on the first PC of methylation, none of them
showed a significant association (p = 0.88 for sex, p = 0.25
for passage number, p = 0.21 for number of Y chromo-
somes, p = 0.65 for age; see also Additional file 8: Table S5).
In contrast, a linear model that regressed, individually, the
number of X chromosomes and SRY on the first PC of
methylation showed significant associations (p = 0.019 for
number of X chromosomes, p = 0.037 for SRY).
Stepwise regression, using likelihood ratio tests, to choose
variables for inclusion and exclusion selected a final model
with covariates sex, SRY, number of X chromosomes, and
an interaction between the latter two variables (Table 2 and
Fig. 1b). All multiple regression models excluded one sam-
ple with ambiguous sex, and therefore, sample size was 28
in these models. The significant interaction between the
number of X chromosomes and SRY presence on the
methylation patterns is such that the relationship between
methylation and the number of X chromosomes is mainly
evident when SRY is absent (Fig. 1b). In the absence of SRY,
methylation was higher in the samples with two or more X
chromosomes, when compared to a reference group of
samples with one X chromosome (Fig. 1b). In the presence
of SRY, however, the number of X chromosomes appears to
have little influence on ZPBP2 methylation (Table 3),
although only three samples with SRY and two or more X
chromosomes were available for analysis. We realize that
due to the numbers of non-transformed fibroblast samples
available for this analysis that power is limited (see Table 1
and Table S5); nevertheless, given that only one multiple
linear model was fit, no adjustments for multiple compari-
sons were performed.
Stepwise multiple linear regression results, chosen
by comparing model fits with likelihood ratio tests,
between the first PC of methylation data at ZPBP2
and covariates. Estimates and standard errors are in
Fig. 1 Effect of sex and the sex chromosome complement on ZPBP2 methylation levels. a Methylation levels of 10 CGs located within the ZPBP2
promoter region in fibroblast cell lines from 46,XX females, 46,XY males, 45,X females, 46,XY females, and 46,XX males. b Results of linear
regression analysis showing means and 95% confidence intervals of the first principal component, averaged over the two sexes. The differences
are interpretable as changes in percent methylation, although the exact values are intercept adjusted. Left: one X chromosome; right: 2 or more
X chromosomes. Within each panel, SRY is denoted as absent or present
Table 2 Multiple linear regression results between the first PC
of methylation data and covariates
Covariate Estimate Std. error t value Pr(>|t|)
(Intercept) − 19.44 13.63 − 1.426 0.167
Sex: male 25.90 12.78 2.027 0.054
Presence of SRY − 3.542 16.81 − 0.211 0.835
Two or more X chromosomes 35.00 15.28 2.291 0.032
Interaction: SRY: two or more
X chromosomes
− 51.38 22.41 − 2.293 0.031
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units of methylation percentages. The number of
samples in all analyses is 28. This model has an
adjusted R-squared of 0.30 and a naïve R-squared of
0.41. Note that the p value of 0.054 for “sex” is
obtained from a Wald test; this variable was retained
in the model based on a likelihood ratio test with
p = 0.032.
The results are estimated from the multiple linear
regression in Table 2 and averaged over the two sexes.
The X-linked modifier of DNA methylation maps to
chromosomal region Xq13-Xq21
Since the X chromosome dosage influenced methylation,
the next step was to map the region of the X chromosome
harboring the gene(s) responsible for this influence. We
reasoned that the X-linked modifier of DNA methylation
should satisfy the following criteria: (i) two or more copies
of the modifier would result in higher methylation levels
compared to one copy and (2) loss of function mutations
in the modifier in 46,XX females would result in lower
methylation levels at the reporter locus.
We first asked if the X-linked modifier resided on the Xp
or Xq arms and compared ZPBP2 methylation in fibroblast
cell lines from four Turner syndrome patients with mono-
somy X (45, X), four individuals with monosomy for most
of the p-arm and trisomy for the q-arm of X chromosome
(referred to as 46,X,i(Xq)) and three females with trisomy X
(47 or 48,XXX) (Fig. 2a). Since the SRY region may reduce
methylation levels in samples with two or more X chromo-
somes, we selected cell lines in which SRY was absent. The
methylation levels at individual CGs within the ZPBP2
DMR were correlated (Pearson correlation coefficient ran-
ging from 0.36 to 0.85). Hence, we used the average methy-
lation levels across the 10 CGs as a read-out. Fibroblast cell
lines from Turner syndrome patients with monosomy X
had significantly lower methylation levels than those with
three copies of the Xq (p = 0.00013, one-tailed Student’s t
test) (Fig. 2b). A similar trend was observed in the extended
ZPBP2 promoter region (Additional file 5: Figure S2B).
Therefore, at least one of the genes that influence ZPBP2
DMR methylation resides on the long arm of the X
chromosome.
To test the possibility that the number of inactive X
chromosomes rather than the dose of a particular gene
influenced ZPBP2 DMR methylation levels, we com-
pared females with two inactive X chromosomes (Xi)
and three copies of Xq (47/48,XXX) to those with one
Xi and three copies of Xq (46,X,i(Xq)). No significant
differences in methylation levels were found between
these two groups (p = 0.13, one-tailed Student’s t test).
Methylation in 46,X,i(Xq) samples was not statistically
different from that in 46,XX females (p = 0.49, two-tailed
Student’s t test).
Next, to further reduce the candidate region for the
Xq-linked methylation modifier(s), we examined four
fibroblast cell lines from females with different Xq dele-
tions (Fig. 2a). ZPBP2 methylation levels in these cell
lines were higher than in 45,X Turner syndrome patients
(Fig. 2b). We hypothesized that all four cell lines with
Xq deletions contained two or more copies of the X-
linked modifier. Two Xq regions, referred to as region 1
and region 2 from this point on, were present in all four
cell lines in more than one copy (Fig. 2a). Therefore, if
there was only one methylation modifier in Xq, it had to
reside in one of these two regions. Region 1 spans more
than 10 Mb between the centromere and genomic pos-
ition 78.6 Mb (hg19) (Xq11-q21) and includes the X-
inactivation center. Region 2 spans a 2.2 Mb genomic
interval between positions 106.6 and 108.8 Mb (Xq22.3)
of the X chromosome and includes 18 annotated genes.
We next hypothesized that if region 1 harbored the X-
linked modifier of methylation, female carriers of
chromosomal duplications of this region would have
higher methylation levels than females without duplica-
tions. There were no fibroblast cell lines with duplica-
tions of the Xq11-q21 region available to us. We
therefore assayed ZPBP2 methylation in peripheral blood
of three females who carried duplications of chromo-
somal region Xq13.2-q21.1 [29, 30] and compared their
methylation levels to those observed in the blood of con-
trol females and males from the SLSJ familial collection
[6] (Fig. 2c). Methylation in the duplication carriers was
at the higher end of the range observed in non-carrier
females, and the difference reached statistical signifi-
cance in our sample (p = 0.0045, two-tailed Student’s t
test) (Fig. 2c). Based on the boundaries of these duplica-
tions, we speculate that the candidate gene may reside
within a 5.2 Mb genomic interval between genomic posi-
tions 73.1 and 78.4 (hg19) (Fig. 2a); however, this con-
clusion must be validated using a larger sample size.
Two genes, the ATRX, chromatin remodeler (ATRX)
and ring finger protein, LIM domain interacting (RLIM)
reside in region 1 and are of particular interest because
they encode transcription factors that are involved in epi-
genetic silencing and X chromosome inactivation [36–40].
These genes are subject to X-inactivation [41], but could
act before its onset in early embryos. In such a case, the
mutation would have an effect independent of whether it
resided on the X chromosome that was preferentially inac-
tivated. We therefore hypothesized that if ATRX or RLIM
Table 3 Differences from average methylation as a function of
number of X chromosomes and SRY
SRY Number of X chromosomes
One Two or more
Absent − 11.11 23.89
Present − 14.65 − 31.03
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influenced ZPBP2 methylation, their mutations would
reduce methylation levels in heterozygous carrier females.
ZPBP2 methylation levels were assayed in two female
carriers of the disease-causing ATRX mutation
c.7366_7367insA [31] and eight heterozygous carrier
females of the disease-causing mutation p.Arg387Cys in
the zinc-finger domain of RLIM [32]. The samples from
six female relatives of the RLIM mutation carriers were
also assayed. ZPBP2 methylation levels in female carriers
of RLIM and ATRX mutations were not different from
those found in controls (Fig. 2c). Thus, neither ATRX nor
RLIM mutations reduced the methylation levels of ZPBP2
in heterozygous females in our study.
Discussion
Here, we report that X-chromosome dosage and sex
determining factor SRY region contribute to sexual
dimorphism in DNA methylation at an autosomal
region, the promoter/enhancer of the ZPBP2 gene
located in chromosomal region 17q12, whereas pheno-
typic sex and age have no significant effect on methyla-
tion. The presence of the whole Y-chromosome or its
part harboring the SRY gene were associated with lower
methylation levels, independent of the number of X
chromosomes. To the best of our knowledge, this is the
first study of the effect of sex chromosomes and sex
phenotype on autosomal methylation in human cells.
In the DNA samples from Turner syndrome patients
that carried only one X, the ZPBP2 DMR methylation
levels were lower than in individuals who carried two or
more copies of intact X chromosomes, or the Xq arms.
Our findings are consistent with hypomethylation of the
ZPBP2 promoter region in the blood cells of Turner
syndrome patients compared to 46,XX females [24, 25].
Fig. 2 The X-linked modifier of ZPBP2 methylation resides on the q-arm of the X chromosome. a Dosage of X-chromosomal regions in female
fibroblast cell lines and female carriers of Xq10-q21 duplications tested in the study. Regions present in one copy are shown in dark red. Regions
present in three copies are shown in dark blue and in four to five copies in blue. The rest are present in two copies. The cell line ID is shown on
the left. The coordinates of the deletion and duplication boundaries are based on array-CGH data. The possible locations of the X-linked gene that
influences ZPBP2 methylation are shown below the diagram. b Average methylation levels across the 10 CGs of the ZPBP2 DMR in fibroblast cell
lines from Turner syndrome patients with an 45,X karyotype (n = 4) compared to Turner syndrome patients with a 46,X,i(Xq) karyotype (n = 4),
carriers of Xq deletions (n = 4), female carriers of trisomy X (47/48,XXX) (n = 3), 46,XX females (n = 13), and 46, XY males (n = 7). Numbers of
samples, copies of the Xq, and numbers of Xi are shown below the x-axis. c Average methylation levels across the 10 CGs of the ZPBP2 DMR in
peripheral blood cells (PBC) from females (C1, n = 49), non-carrier female relative of RLIM mutation carriers (C2, n = 6), heterozygous female carriers
of Xq13-q21 duplications (n = 3), heterozygous female carriers of an ATRX mutation (n = 2), heterozygous female carriers of an RLIM mutation (n =
8), males (C3, n = 48), and male carriers of Xq13-q21 duplications (n = 2)
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The caveat here is that our conclusions are based on the
assumption that rearrangements and aneuploidy for
chromosomes other than the sex chromosomes are
unlikely to affect ZPBP2 methylation levels. This
assumption has not been tested.
To identify the X-linked genes responsible for the
levels of DNA methylation at the ZPBP2 locus, we com-
pared methylation in fibroblast cell lines from Turner
syndrome patients with karyotypes 45,X and 46,X,i(Xq),
females with trisomy X, as well as females with deletions
within the Xq arm. To confirm the effect of the Xq13-
q21 dosage on ZPBP2 methylation, we used the DNA
samples from peripheral blood cells of female carriers of
Xq13-q21 duplications. The striking differences in
methylation between Turner syndrome patients with
one and three copies of Xq suggest that at least one X-
linked modifier of ZPBP2 methylation levels resides on
the q-arm of the X chromosome. ZPBP2 methylation in
the samples from Xq13-q21 duplication carriers was at
the higher end of the range of controls, but the differ-
ence was not as dramatic as the difference between
males and females. Therefore, using samples from
female carriers of X chromosomal deletions may prove
to be a more informative mapping approach.
The results of testing two candidate genes from region
1, ATRX and RLIM, did not support the hypothesis that
the dosage of either one of these genes was responsible
for the higher methylation of the ZPBP2 DMR in
females. However, it is possible that a missense mutation
in ATRX or RLIM may impact DNA methylation differ-
ently than a deletion of the entire gene would.
In principle, the X-linked gene(s) that is responsible
for the dose-dependent effect on DNA methylation
should either escape X-chromosome inactivation or act
early in embryonic development before the onset of X-
inactivation (reviewed in [42]). In humans, sex differ-
ences in DNA methylation are present in newborns [4]
whereas the earliest developmental stage with sex differ-
ences in human gene expression is represented by
embryonic stem cells [43]. Sex differences in gene ex-
pression are detected in embryonic stem cells derived
from mouse blastocysts and in bovine blastocysts and as
early as 8-cell stage in mouse embryos [44–46]. Hence,
one cannot rule out the possibility that the causal X-
linked gene contributes to the establishment of sexually
dimorphic DNA methylation patterns before the blasto-
cyst stage, and silencing of one of its copies later in
development does not alter DNA methylation patterns.
Alternatively, if the sexual dimorphism in DNA methyla-
tion is established after the onset of X-inactivation or
the X-linked factor is required for the maintenance of
higher methylation levels in females, the causal X-linked
gene must escape X-inactivation to act in a dose-
dependent fashion. Indeed, the X-linked gene for lysine
demethylase 5C (KDM5C) that escapes X-inactivation
and its Y-homolog KDM5D, both influence DNA methy-
lation at certain autosomal regions in a dose-dependent
fashion [47]. KDM5C resides on the short arm of the X
chromosome and in principle may be responsible for the
tendency to lower methylation in 46,X,i(Xq) compared
to trisomy X females.
None of region 2 genes are known to escape X-
inactivation. Region 1 is larger, and several of its genes
escape X-inactivation including several long non-coding
RNAs (e.g., X-inactive specific transcript (XIST), JPX
transcript, XIST activator (JPX)) [41, 48]. Region 1 also
harbors several micro RNAs whose inactivation status is
not known [41, 48]. This warrants further studies of the
role of region 1 genes in the establishment of autosomal
methylation patterns.
X-chromosome inactivation requires epigenetic silen-
cing of hundreds of genes on the same X chromosome.
It has been suggested that the presence of an inactive X
per se may influence the genomic distribution of hetero-
chromatic proteins, acting as an epigenetic “sink” or
“tank” [13, 49–51]. The data from the studies of meiotic
silencing in the mammalian germ line show that, indeed,
sex chromosomes and autosomes may compete for
silencing factors in certain cell types [52–55] landing
additional support for this hypothesis. If this were the
mechanism by which X chromosome dosage affected
autosomal methylation, it would cause differences in
DNA methylation levels between individuals who carry
an inactive X and those who do not. Moreover, one
would predict that the number of inactive X chromo-
somes rather than number of copies of a particular X-
linked gene would be critical. That is, the presence of an
inactive isochromosome Xq would have the same impact
on methylation as would one Xi or an Xi with a duplica-
tion have. Although our data are consistent with the
possibility that the inactive X promotes higher DNA
methylation levels at the ZPBP2 DMR (acting as a “sup-
ply center” rather than a “sink” for heterochromatic fac-
tors), higher methylation in duplication carriers who
have only one Xi, favors the scenario with genes on the
Xp and Xq influencing methylation rather than an effect
of an inactive X being present.
In contrast to the X chromosome, the presence of the
Y-chromosome reduces the level of DNA methylation at
the ZPBP2 DMR and makes it insensitive to the X
chromosome dosage. The SRY region recapitulates the
effect of the whole Y in our small sample of fibroblast
cell lines. SRY is a transcription factor that plays a crit-
ical role in sex determination (reviewed in [56]). More-
over, the mouse Sry has been shown to contribute to
sexual dimorphism in autosomal gene expression levels
[13]. It has been also implicated as the cause of sexual
dimorphism in human brain development [57] and
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Hirschsprung disease [58]. The mechanism of the SRY
effect on methylation has yet to be discovered; however,
it is worth noting that our reporter gene ZPBP2 is highly
expressed in testis and implicated in male fertility [59].
We therefore hypothesize that SRY binds the ZPBP2
promoter and shields it from DNA methylation, thereby
preserving its activity in males, in the germ line, and in
somatic cells. Such a mechanism would be beneficial for
male fertility and explain the enrichment of
spermatogenesis-associated genes among those with sex-
specific promoter methylation [2, 4]. Thus, although SRY
resides within a gene-rich region of the Y chromosome
and, in our study, its effect cannot be separated from the
effects of closely linked genes, it represents a good can-
didate whose role needs further investigation.
Interestingly, in Drosophila, sexual dimorphism in
body size is regulated by the dosage of the X-linked gene
Myc, which is not subject to dosage compensation, and
the sex-determining gene transformer (tra) [10]. Mouse
studies dissecting the mechanism underlying sexual
dimorphism in gene expression levels suggest contribu-
tion of X- and Y- encoded factors as well as sex hor-
mones [13]. Thus, the sum of current data suggests that
the paradigm implicating interaction between X-
chromosome-linked and sex-determining genes in sexual
dimorphism in insects [10, 60, 61] and mice [13] may
also explain some instances of sexually dimorphic auto-
somal DNA methylation in humans. We focused our
study of sexual dimorphism in DNA methylation at a
single autosomal locus. However, our findings may
reflect a more general rule and larger genomic studies
may find similar regulation of methylation at other auto-
somal loci.
Conclusions
Our data demonstrate that interaction between the Y
chromosome and the X chromosome dosage defines
DNA methylation levels at the autosomal locus ZPBP2.
Furthermore, our findings suggest that at least one X-
linked gene that influences ZPBP2 DMR methylation
levels resides on the long arm of chromosome X. This is
the first study that attempts dissecting the genetic mech-
anisms underlying sex-specific differences in methylation
levels in a human autosomal region, and our findings
may be applicable to other loci.
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